Aman Chauhan
Advanced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Aman Chauhan

Oncology
University Of Miami
1611 Nw 12 Ave, 
Miami, FL 
Accepting New Patients
Offers Telehealth
Advanced in Non-Small Cell Lung Cancer (NSCLC)
University Of Miami
1611 Nw 12 Ave, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Aman Chauhan is an Oncologist in Miami, Florida. Dr. Chauhan is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Neuroendocrine Tumor, Small Cell Lung Cancer (SCLC), Merkel Cell Carcinoma, Vaginectomy, and Embolectomy. Dr. Chauhan is currently accepting new patients.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Oncology
Licenses
Internal Medicine in FL
Languages Spoken
English
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

UNIVERSITY OF MIAMI
1611 Nw 12 Ave, Miami, FL 33136

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Procedure, Drug
Study Drugs: Lutetium Lu 177 Dotatate, Triapine
Study Phase: Phase 1
A Phase 1b Trial of M3814 (Peposertib) in Combination With Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
A Phase 1b Trial of M3814 (Peposertib) in Combination With Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Procedure
Study Drugs: Lutetium Lu 177 Dotatate, Peposertib
Study Phase: Phase 1
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: Lutathera, Octreotide
Study Phase: Phase 3
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drug: Lutathera
Study Phase: Phase 2
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, Carboplatin, Cisplatin, Etoposide, Temozolomide
Study Phase: Phase 2
Phase II Study of Combination Rucaparib With Nivolumab in Platinum-Sensitive Small Cell Lung Carcinoma Patients as Maintenance After Induction Therapy With Platinum Doublet
Phase II Study of Combination Rucaparib With Nivolumab in Platinum-Sensitive Small Cell Lung Carcinoma Patients as Maintenance After Induction Therapy With Platinum Doublet
Enrollment Status: Completed
Publish Date: October 22, 2024
Intervention Type: Combination product
Study Drug: Rucaparib+Nivolumab
Study Phase: Phase 2
Study of Telotristat (Xermelo) in Combination With Luetetium Lu177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine Tumors
Study of Telotristat (Xermelo) in Combination With Luetetium Lu177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine Tumors
Enrollment Status: Terminated
Publish Date: June 27, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Feasibility Study of Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma
A Pilot Feasibility Study of Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma
Enrollment Status: Completed
Publish Date: May 17, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Phase 1 Study of Fosbretabulin in Combination With Everolimus in Neuroendocrine Tumors (Grades 1-3) That Have Progressed After at Least One Prior Regimen for Metastatic Disease
A Phase 1 Study of Fosbretabulin in Combination With Everolimus in Neuroendocrine Tumors (Grades 1-3) That Have Progressed After at Least One Prior Regimen for Metastatic Disease
Enrollment Status: Terminated
Publish Date: August 08, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

94 Total Publications

Evolving strategies in the management of non-small cell lung cancer brain metastases: insights from the C-Brain trial.
Evolving strategies in the management of non-small cell lung cancer brain metastases: insights from the C-Brain trial.
Journal: Chinese clinical oncology
Published: August 21, 2025
Similar Doctors
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Luis E. Raez
Hematology Oncology | Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Luis E. Raez
Hematology Oncology | Oncology

South Broward Hospital District

1150 N 35th Ave, Suite 170, 
Hollywood, FL 
 (15.9 miles away)
954-265-4325
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Luis Raez is a Hematologist Oncology specialist and an Oncologist in Hollywood, Florida. Dr. Raez is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Raez is currently accepting new patients.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Gilberto L. Lopes
Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Gilberto L. Lopes
Oncology

University Of Miami

1611 Nw 12 Th Ave, Jackson Memorial Hospital, 
Miami, FL 
 (0.1 miles away)
305-355-5000
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Gilberto Lopes is an Oncologist in Miami, Florida. Dr. Lopes is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, and Colorectal Cancer. Dr. Lopes is currently accepting new patients.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Mohammad Jahanzeb
Oncology | Hematology Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Mohammad Jahanzeb
Oncology | Hematology Oncology
1192 E Newport Center Dr, Suite 100, 
Deerfield Beach, FL 
 (35.6 miles away)
954-571-0111
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Accepting New Patients

Mohammad Jahanzeb is an Oncologist and a Hematologist Oncology provider in Deerfield Beach, Florida. Dr. Jahanzeb is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma. Dr. Jahanzeb is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chauhan's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile